Research Article

Overexpression of ABCC2 and NF-Kβ/p65 with Reduction in Cisplatin and 4OH-Tamoxifen Sensitivity in MCF-7 Breast Cancer Cells: The Influence of TNF-α

Nafiseh Sadat Alamolhodaei[1], Hatam Rashidpoor[1], Melika Ehtesham Gharaee[1], Javad Behravan[2], Fatemeh Mosaffa[3]*

[1]*Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.*
[2]*School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.*
[3]*Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.*

Abstract

Background: TNF-α, as a pro-inflammatory cytokine in the tumor microenvironment is able to regulate the expression and function of various ATP binding cassette (ABC) transporters involved in clinical drug resistance and among them, ABCC2 transporter is represented to contribute to cancer multidrug resistance (MDR) by drug efflux.

Methods: In this study, we aimed to evaluate the effects of TNF-α and/or E2 (17β-estradiol) on the mRNA and protein expression levels of ABCC2 and NF-κB (p65) transcription factor in estrogen receptor positive (ER+) MCF-7 cells by QRT-PCR and Western blot analysis. Also, we used MTT assay to study the cell sensitivity against the active form of tamoxifen (4OH-TAM), a hypothetical substrate and Cisplatin (Cis), a well-known substrate for ABCC2 used in endocrine and chemo-therapy of breast cancers, respectively. Data were analyzed by one-way ANOVA and Tukey tests. Significance was considered in P-values < 0.05.

Results: The expression levels of ABCC2 and the active form of NF-κB (p65) were significantly increased following 20-day concomitant treatment with TNF-α and E2, compared to untreated cells as control. Also, the viability assay showed that 20-day TNF-α+E2 treatment led to more sensitivity reduction of MCF-7 cells to Cis and 4OH-TAM compared to E2-treated and untreated cells.

Conclusion: Based on our findings, there is a positive correlation between ABCC2 overexpression, over-activity of NF-κB/p65 and decreasing the sensitivity of MCF-7 cells to Cis and 4OH-TAM following TNF-α treatment in MCF-7 cells. Further experiments are needed to elucidate possible mechanistic relationship of these findings and their clinical significance in order to circumvent the drug-resistance in breast tumors.

Introduction

With no doubt, there is a strong connection between inflammation and cancer.[1] TNF-α, one of the outstanding pro-inflammatory cytokines, initially found as a result of its antitumor activity, has now been represented to be one of the important mediators of inflammation. It is present in cancer microenvironment and is secreted by infiltrating immune and stroma cells (mainly by tumor-associated macrophages) or even tumor cells themselves. TNF-α expression is high in biopsies and in the plasma of patients with multiple advanced cancers.[2] There is a link between chronic, low level TNF-α exposure and the acquisition of some tumor properties such as tumor proliferation, angiogenesis and metastasis.[3] On the other hand, it can influence the sensitivity of the tumor cells to drug treatment which is associated with both endocrine and chemo-therapy failures.[4-6]

Multidrug resistance (MDR) is a major problem in cancer therapy. In this phenomenon, exposure of cancer cells to a chemotherapeutic drug may result in resistance to it and also cross resistance to many other structurally and mechanically different chemotherapeutics.[7] MDR may occur due to different mechanisms including decreased drug accumulation and increased drug efflux, alterations in drug target, over-activity of drug detoxifying enzymes, activation of DNA repair mechanisms, alterations in cell cycle regulation, evasion of apoptosis and the overexpression of ATP-binding cassette (ABC) transporters that pump out chemotherapeutics.[8-10]

ABCC2 or the multidrug resistance protein 2 (MRP2) called canalicular multi-specific organic anion transporter (cMoat) is a transmembrane ABC transporter placed at

the canalicular domain of hepatocytes. It is also found in most excretory organs such as renal, small intestine, colon, gall bladder, and lung.[11,12] Notably, ABCC2 is expressed in malignant tissues and plays a pivotal role in the transport of chemotherapeutic agents (e.g. methotrexate, vinca alkaloids and anthracyline) and different conjugated metabolites.[13,14]

Cis (Cis- dichlorodiammine platinum (II) (CDDP)) is a well-known and the first platinum-containing chemotherapeutic drug used to treat a wide range of human malignancies for example testicular, head and neck, esophageal, lung, ovarian and breast.[15,16] Various factors influence the uptake of Cis including sodium and potassium ion concentrations, pH, the attendance of reducing agents, and especially transporters.[17] ABCC2 is one of the key actors of Cis transporting across the cell.[18,19] From the past until now, many evidences have highlighted the importance of ABCC2 efflux pump in drug resistance in different cell lines such as human embryonic kidney (HEK-293),[20] Cis-resistant human cell lines (T24IDDP1O , P/CDP5and KB/KCP4),[21] and two human gastrointestinal tumor cell lines (HepG2 and PANC-1).[22] The expression of ABCC2 transporter could also be considered as an important biomarker for Cis chemotherapy response in different solid tumors.[23,24]

TAM as a selective estrogen receptor modulator (SERM) is the basis of anti-estrogen therapy for ER+ breast cancers composed of 75% of breast tumors.[25,26] Acquired resistance to TAM is a major obstacle to effective endocrine therapy in breast cancer patients. To our knowledge, tamoxifen could be a substrate for ABC transporter proteins and its intracellular accumulation is affected by efflux transporters.[27,28]

Increasing number of studies showed that the expression levels of ABCC2 is higher in TAM- resistant in comparison with TAM-sensitive breast cancer cells; Therefore, it has been speculated that ABCC2 might participate in efflux of the active metabolites of TAM (e.g.4OH-TAM) from breast cancer cells.[28-30]

Furthermore, it has been shown that ABCC2 is also overexpressed in breast tumors and it has some effects on TAM clinical efficacy.[31,32]

Plenty of studied have revealed that the expression or activity of different ABC transporters at various levels of expression (transcriptional, post-transcriptional, translational, and post-translational levels) might be influenced by proinflammatory cytokines such as TNF-α.[33-35]

NF-κB transcription factor is an important regulator of inflammation and its constitutive activation have reported in tumors with a high risk for recurrence.[36,37] On the other hand, NF-κB is one of the proved downstream mediator of TNF-α signaling and it has shown to be involved in the alteration of ABC transporters expression mediated by TNF-α.[38,39]

As TNF-α proved to be present in the microenvironment of breast tumors,[3] for the first time we evaluated its effects on mRNA and protein expression of ABCC2 transporter in long term (20-day) treatment in MCF-7 (ER+) breast cancer cells, in the presence of E2 as one of the represented growth stimulators in ER+ breast carcinoma cells.[40] We also checked the sensitivity of TNF-α treated cells against breast cancer chemotherapeutic agent, Cis, which is a well-known ABCC2 substrate.[18] Furthermore, a probable substrate of this transporter, 4OH-TAM, used widely as the basis of anti-estrogen therapy for ER+ breast cancers was investigated.[26] Then, the possible correlation between change in expression levels of ABCC2 transporter, NF-κB/p65 nuclear transcription factor and TNF-α/E2 treatment was investigated.

Materials and Methods
Cell culture and Reagents
MCF-7 cell line was provided from Pasteur Institute, Tehran, Iran. Cells were cultured in RPMI-1640, supplemented with FBS (Fetal Bovine Serum) 10% (v/v) (GIBCO, Grand Island, NY, USA), penicillin (100 units/ml), and streptomycin (100 μg/mL) (GIBCO, Grand Island, NY, USA) at 37˚C in the presence of 5% CO2.

TNF-α and 4OH-TAM were purchased from Millipore, USA. 5mM 4OH-TAM stock was prepared by Ethanol 100% (v/v) as solvent and stored in -80 ˚C. Cis vial for injection (10mg/10ml) was purchased from MYLAN (France).

Cell treatments and viability assay
The influence of TNF-α in the presence of E2 on cell viability was assessed by MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) assay. Morphologic changes were examined under an INVERSO-TC100 phase-contrast microscope (Medline Scientific Limited, Oxford shire, United Kingdom).

20-day TNF-α and/or E2 treatment
Cells were treated with TNF-α (10ng/ml) +E2 (10nM) or E2 (10nM) alone for 20 days. The media was replaced with fresh one containing TNF-α and/or E2 every 3 days. Control cells were treated only with culture medium.

Cis-treatment
After 20-day TNF-α/E2 treatment, the sensitivity of MCF-7 cells to Cis was analyzed by MTT assay. Cells were cultivated in 96-well plates at a density of 1.0×10^4 cells/well and then treated with increasing concentrations of Cis (12.5, 25, 50 and100 μM) for 48 h.

TAM-treatment
After 20-day TNF-α/E2 treatment, TAM sensitivity was assessed by MTT method. Cells were cultivated in 96-well plates at a density of 3.0×10^3 cells/well and then treated with increasing concentrations of 4OH-TAM (0.001, 0.01, 0.1, 0, 1, 10 and 15μM) for 5 days. (Control cells: treated only with the culture medium and ethanol 1% (v/v)).
At the end of incubation period with 4OH-TAM and Cis,

20 µL MTT solution was appended to each well for 3 h. Thereafter, to solubilize the formazan crystals, 200 µL of dimethyl sulfoxide (DMSO) was added to each well and the absorbance was determined at 570 nm on an ELISA plate reader (Biotek®). Values were corrected for background absorbance at 630 nm. Three independent experiments, at least three wells for each time and concentration point, were evaluated; and cell viability was calculated as a percentage of negative controls.

Quantitative reverse transcription polymerase chain reaction (QRT-PCR)

The mRNA levels of ABCC2 transporter and NF-κB /p65 transcription factor were examined by QRT-PCR. Total RNA was extracted from treated and control cells. RNA isolation and then cDNA synthesis with the final evaluation step of expression, RT-PCR, were done according to the manufacturer's instructions (Yekta Tajhiz Azma kit, Iran) using specific primers (Table 1). PCR was performed for 40 cycles following thermal cycling conditions: 95 ˚C for 3 min (initial denaturation), 95 ˚C for 5 s (denaturation) and

Table 1. Lists of primers in QRT-PCR.

Genes	Sequences
ABCC2	Forward: 5′-ACAGAGGCTGGTGGCAACC-3′ Reverse: 5′-ACCATTACCTTGTCACTGTCCATGA-3′
NF-κB /p65	Forward: 5′- CCTTATCAAGTGTCTTCCATCA-3′ Reverse: 5′- AATGCCAGTGCCATACAG-3′
β-actin	Forward: 5′- TCATGAAGTGTGACGTGGACATC-3′ Reverse: 5′-CAGGAGGAGCAATGATCTTGATCT-3′

60 ˚C for 1 min (annealing/extension).
At the end of the PCR cycles, the PCR products were examined using a melting curve analysis by slowly increasing the temperature from 60 ˚C to 95˚C to indicate the absence of non-specific products detected by SYBR Green dye. Standard curves were delineated for the target (ABCC2, NF-κB/p65) and reference (β-actin) genes. Calibrator-normalized relative quantification with efficiency correction was performed using the Applied Biosystems Software (StepOne software). The results were represented as the target/reference ratio of the cytokine+E2 or E2-treated samples divided by the target/reference ratio of the calibrators (untreated sample).[41,42]

Western blot analysis

Western blot analysis was used to assess the levels of cytoplasmic (ABCC2) and nuclear protein expression (NF-κB/p65) in treated and control cells using nuclear protein

extraction kit (abcam® (USA), CAT. NO: ab113474). According to kit protocol, 100 µL of 1X Pre-Extraction Buffer containing DithioThreitol (DTT) and Protease Inhibitor Cocktail (PIC) at a 1:1000 ratio was added to cell pellet. After vortexing for 10 s and incubation on ice for 10 min, cytoplasmic proteins were carefully removed from nuclei by centrifugation for 1 minute at 12,000 rpm and then transferred to another micro-centrifuge vial. Nuclear protein extract was prepared according to protocol of nuclear protein extraction kit. DTT Solution and PIC was appended to Extraction Buffer at a 1:1000 ratio. After Adding 2 volumes of Extraction Buffer containing DTT and PIC to nuclear pellet (about 10 µL per 10^6 cells), the extract was incubated on ice for 15 minutes with vortex every 3 minutes. The extract can be further sonicated for 3 x 10 seconds to increase nuclear protein extraction. Before transferring the supernatant into a new micro-centrifuge vial, the suspension was centrifuged for 10 minutes at 14,000 rpm at 4°C and the protein concentration of the nuclear extract was measured. The Bradford Reagent was used to measure the protein concentration of the nuclear and cytoplasmic extracts. The fractionated proteins were then sample transferred electrophoretically to (poly vinylidene difluoride) (PVDF) membranes (Bio-Rad, Hemel Hempstead, UK) and the proteins were immunoblotted with the specific antibodies. Primary antibodies against β-actin, ABCC2 and NF-κB/p65 (all purchased from Cell Signaling Technology, Beverly, MA, USA) interacted with secondary horseradish peroxidase–linked anti-mouse or anti-rabbit conjugate antibodies (Table 2). Protein bands were appeared by Enhanced chemiluminescnce (ECL) reagent (Pierce Rockford, IL, USA) and Alliance 4.7 Geldoc (UK).[34,43]

Statistical analysis

Results were expressed as mean ± SD (standard deviation) of at least three independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) and Tukey-Kramer test with GraphPad Prism5. Significance was considered in P-values < 0.05.

Results

Effect of TNF-α/E2 on Cis-sensitivity of MCF-7 cells

Following 20-day TNF-α and/or E2 treatment, concentration dependent reduction in cell viability was observed after 48 h incubation period with increasing concentrations of Cis (12.5, 25, 50 and100 µM). At 12.5 to 50 µM, mean cell viability was higher in MCF-7 cells treated with TNF-α+E2 (IC50: 67.1866±6.5), compared to both E2 treatment alone (IC50: 40.5333±4.45) and

Table 2. Lists of antibodies in western blot analysis.

| Ab	CAT. NO	Company	Volume/MW
Anti-rabbit NF-κB mAb	4764S	Cell Signaling	100 µl/65KDa
Anti-rabbit IgG, HRP-linked Antibody	7074P2	Cell Signaling	100 µl
Anti-rabbit MRP2/ABCC2 mAb	12559S	Cell Signaling	100 µl/200KDa
Anti-mouse β-Actin mAb	4970S	Cell Signaling	100 µl/40KDa

Figure 1. Effect of E2 and TNF-α+E2 on sensitivity of MCF-7 cells to Cis following 20-day treatment with E2 (10nM), TNF-α (10ng/ml) and then Cis (12.5, 25, 50 and100 μM) for 48 h analyzed by MTT method. Data are represented as the mean ± SD. Statistics were calculated by one-way ANOVA. At each point: P < 0.05 *, n=3


Figure 2. Effect of E2 and TNF-α+E2 treatment on sensitivity of MCF-7 cells to 4OH-TAM. Following 20-day treatment with E2 (10nM) or E2+TNF-α (10ng/ml) treatment, cells treated with 4OH-TAM (0.001, 0.01, 0.1, 0, 1, 10 and 15μM) for 5 days and cell viability (% of control) was analyzed by MTT method. Data are represented as the mean ± SD. Statistics were calculated by one-way ANOVA. At each point: P < 0.05 *, n=3

untreated cells (IC50: 36.1233±3) (Figure 1).

Effect of TNF-α/E2 on TAM-sensitivity of MCF-7 cells

Following 20-day TNF-α and/or E2 treatment, and then 5-day incubation period with increasing concentrations of 4OH-TAM (0.001, 0.01, 0.1, 0, 1, 10 and 15 μM), concentration dependent reduction in cell viability was observed. At concentrations lower than 10 μM, mean cell viability was higher in MCF-7 cells treated with TNF-α+E2, compared to both E2 treatment alone and untreated cells (Figure 2 and 3).

Effect of TNF-α on mRNA expression of ABCC2 transporter and NF-κB/p65 nuclear transcription factor

20-day TNF-α and/or E2 treatment was associated with significant increase in relative mRNA level of ABCC2 (***p< 0.0001). Remarkable elevation in fold change of ABCC2 mRNA expression was occurred after 20-day TNF-α+E2 concomitant treatment (10.016 ± 0.1 folds); while, after 20-day E2 treatment alone mRNA overexpression was about 2.451 ± 0.2 folds, compared to untreated cells as control (Figure 4A).

To evaluate the correlation between the NF-κB/p65 nuclear transcription factor and ABCC2 gene expressions, NF-κB/p65 mRNA level was examined and compared with the patterns of ABCC2 mRNA expression. Significant elevation in NF-κB/p65 mRNA level (2.483 ± 0.3 folds) (**p< 0.004) was obtained following 20-day TNF-α+E2 treatment, compared to control. On the other hand, treatment with E2 (without TNF-α) did not significantly alter NF-κB/p65 mRNA expression (Figure 4B) (p > 0.05).

Effect of TNF-α on protein expression of ABCC2 transporter and activity of NF-κB (p65) transcription factor

Western blot analysis showed that after 20-day TNF-α+E2 treatment, protein expression of ABCC2 was significantly changed, relative to untreated cells as control (2.869 ± 0.2 folds) (**p<0.001). Increase in ABCC2 expression was also seen following 20-day E2 treatment alone 1.717 ± 0.006 folds) (*p<0.05) not as much as concomitant treatment with TNF-α and E2 (Figure 5A, C). As demonstrated in Figure 5B and C, the level of active form of NF-κB (p65) in nuclear protein extract was significantly enhanced in TNF-α+E2 treated cells following 20-day treatment (2.167 ± 0.1


Figure 3. Effect of TNF-α+E2 treatment on sensitivity of MCF-7 cells to 4OH-TAM. Following 20-day treatment with E2+TNF-α (10ng/ml), cells incubated with 4OH-TAM (0.001, 0.01, 0.1, 0, 1, 10 and 15μM) for 5 days and microscopic studies conducted.

Figure 4. Effect of E2 and TNF-α+E2 on mRNA levels of ABCC2 (A) NF-κB/p65 nuclear transcription factor (B) following 20-day treatment in MCF-7 cell line. mRNA expression was determined by QRT-PCR and normalized to β-actin. Data were analyzed by one-way ANOVA and Tukey-Kramer test. Data are represented as mean±SD. At each point: P < 0.05 *, n=3

folds) (**p< 0.001). E2 treatment was also significantly associated with some elevation in protein expression (1.404 ± 0.04) (*p<0.05), compared to control.

As a result, TNF-α+E2 concomitant treatment induced overexpression of both ABCC2 and NF-κB/p65 proteins stronger than E2-treated and untreated MCF-7 breast cancer cells.

Discussion

Now, it is well understood that inflammation has a key role in all aspects of tumor biology.[44] It has been shown that TNF-α as a pro-inflammatory cytokine is able to modulate the expression of ABC transporters involved in cancer MDR. In this way, the cytokine might be involved in endocrine and chemotherapy response and therefore, elucidating its effects and mechanisms of action in the tumor microenvironment can be helpful in the designing new strategies to circumvent ABC-related drug resistance.[45-47] In this study, we tried to investigate the influence of long-term TNF-α exposure in the presence of E2 as an important


Figure 5. Effect of E2 and TNF-α+E2 on ABCC2 (A) and NF-κB/p65 (B) protein expression, following 20-day treatment in MCF-7 cell line. Protein expression was determined by western blot analysis and normalized to β-actin. Protein bands were appeared by Alliance 4.7 Geldoc (UK) (C). Statistics were calculated by one-way ANOVA and Tukey-Kramer test. Data are represented as mean±SD. At each point: P < 0.05 *, n=3

hormone and one of the represented growth stimulators in ER+ breast carcinoma cells[40] on ABCC2 mRNA and protein expression to mimic the inflammatory condition of the tumor microenvironment and elucidating its effect on Cis and TAM sensitivity in MCF-7 breast cancer cells. In our previous preliminary studies on the expression and activity of ABC transporters modulating by TNF-α in MCF-7 cells, we found that the maximum modulation of ABC transports occurred following 20-day concomitant treatment with both the cytokine and E2 (data not shown). No further change happened in longer incubation periods. Therefore, we treated cell with the cytokine in the presence of E2 for 20 days.

The overexpression of ABCC2 transporter is highlighted in human carcinomas such as renal cells, gastric, colon, lung, ovarian and breast carcinomas correlated with a higher histological grade and poor differentiation, compared with well-differentiated tumors and also ABCC2-mediated anti-cancer drug resistance.[10,23] In support of this, there is a potential role for ABCC2 in Cis resistance by cellular efflux of Cis as a useful anti-cancer agent.[21,48] Of interest is the fact that in both Cis-resistant human epidermoid cancer KB and human prostatic cancer PC-3 cell lines, the ATP-dependent active efflux system of Cis is increased.[49,50] In another study, overexpression of ABCC2 increased the efflux of some chemotherapeutic agents in human embryonic kidney (HEK-293) and the resistance to GSH Cis conjugate was the maximum (10-fold) compared to other compounds.[20] Taniguchi et al, demonstrated that in three Cis-resistant human cell lines (T24IDDP1O from human bladder cancer T24 cells, P/CDP5 from human prostatic cancer PC-3 cells and KB/KCP4 from human head and neck cancer KB cells) the mRNA of ABCC2 transporter was expressed 4- to 6-fold higher than parent cells correlated with decreased cellular Cis- accumulation.[21] The effect of ABCC2 tumor expression on the efficacy of Cis- treatment in patients with hepatocellular carcinoma was determined by immunohistochemical and Western blot analyses. In line with Korita et al. study, ABCC2 overexpression was significantly associated with a lower percentage of tumor necrosis by Cis chemotherapy (19% vs. 99%, P<0.05).[24] Recent studies have revealed that conferring resistance to oxaliplatin as a common clinical treatment of gastrointestinal cancers is modulated by ABCC2 efflux pump.[22,51] In our study, mRNA and protein expression levels of ABCC2 were significantly greater in 20-day TNF-α+E2 treated MCF-7 breast cancer cells, compared to untreated or even relative to E2-treated cells. Cis is the well-known substrate of ABCC2 transporter[18] and in line to this fact, we also observed more reduction in Cis sensitivity of MCF-7 cells treated with TNF-α+E2, compared to both E2-treated and untreated cells. Adding validity to our findings, in a recent clinical study, the expression of ABCC2 was higher in recurrent tumor compared to paired primary tumor of each patient who is received chemotherapy, highlighting ABCC2 potential role in multiple drug resistance.[52]

TAM is the main anti-estrogen medicine in ER+ breast cancers.[53] Unpredictable response and development of TAM resistance remain a big challenge in ER+ breast cancer management.[29] It has been shown that the tumor microenvironment can modulate TAM resistance by different molecular mechanisms. A study reported that fibronectin in tumor microenvironment conferred resistance to anti-estrogen TAM via interaction with β1 integrin and through activation of some kinase pathways (phosphatidylinositide 3-kinase/serine/threonine-specific protein kinase (PI3K/AKT) and mitogen-activated protein kinase/extracellular signal–regulated kinases (MAPK/ERK)).[54] In human MCF-7 breast cancer cells, TNF-α activated unliganded ERα through kinase-mediated phosphorylation events (IKKβ phosphorylation of S305), then phospho-S305 caused structural changes in ERα and as a consequence, TAM resistance occurred.[4]

It has been observed that after upregulation of ABCC2 efflux transporter, the sensitivity of MCF7 breast cancer cells to TAM (1μM) reduced.[28] In another study, the expression level of ABCC2 was higher in TAM-resistant breast cancer cells (TAMR-MCF-7) compared to the control cells.[30] Based on a clinical study on breast cancer patients in Japan, polymorphism in *ABCC2* gene could be a good predictor for breast cancer prognosis treated with tamoxifen.[32] Also, nuclear expression of ABCC2 in tumor cells was linked to more aggressive and TAM-resistant breast cancers.[12]

TAM is speculated to be a possible substrate of ABCC2 pump;[28] in this regard, in the present study we also investigated the effect of TNF-α and E2 on breast cancer cells sensitivity to 4OH-TAM and we showed simultaneous increase in expression level of ABCC2 and reduction of TAM sensitivity following concomitant treatment.

Activation of well-known NF-κB transcription factor, is associated with both endocrine and chemotherapy failures in breast tumors.[55] It has been shown that one possible pathway in endocrine-therapy resistance is the activation of NF-κB via the PI3K/AKt signaling pathway in MCF-7 breast cancer cells.[56] Activation of anti-apoptotic pathway via nuclear localization of NF-κB, was associated with tumor resistance to anthracycline-based chemotherapy in human breast cancers.[57] TNF-α is one of the most influential activators of NF-κB signaling pathway.[58] Over-activity of NF-κB in ER+ breast tumors caused both mRNA and protein overexpression of ABCG2.[38] We previously demonstrated that over-activity of NF-κB/p65 following TNF-α treatment was concomitant with overexpression of ABCG2 in breast cancer cell lines (MCF-7, BT-474, and CAL51).[34] Notably, functional NF-κB binding site is present in the promoter of ABCC2 gene.[59] Not only in breast tumors, but also in other cancer cell lines, it has also illustrated a role for NF-κB in regulating the expression of ABC transporters, conferring chemoresistance.[6,60] In line with these evidences, we also found that following 20-day treatment with TNF-α+E2, the mRNA and protein levels of active form of NF-κB (p65) were significantly increased,

compared to untreated cells as control. These observations might propose the possibility of linkage between over-activity of NF-κB/p65, ABCC2 overexpression and also Cis and TAM drug resistance in MCF-7 breast cancer cells.

Conclusion

Above-mentioned studies have highlighted that TNF-α is involved in mediating inflammation in breast tumor microenvironment leading to tumor proliferation, invasion and resistance properties. In this study, we tried to mimic the inflammatory condition of the tumor microenvironment for the MCF-7 breast cancer cells by TNF-α exposure in order to study its effect on Cis and TAM sensitivity in MCF-7 cells. Based on our findings, the cytokine could induce reduction in Cis and TAM sensitivity that was correlated with increase in expression levels of ABCC2 and NF-κB/p65 activity in MCF-7 breast cancer cells. Further experiments are needed to elucidate possible mechanistic relationship of these findings and their clinical significance in order to circumvent the drug resistance in breast tumors.

Acknowledgments

Conflict of Interests

The authors declare that they had no conflict of interests.

References

1. Crusz SM, Balkwill FR. Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584-96. doi:10.1038/nrclinonc.2015.105
2. Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: Molecular insights and therapeutic approaches. Cell Oncol. 2020;43(1):1-18. doi:10.1007/s13402-019-00489-1
3. Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015;35(1):1-16. doi:10.1089/jir.2014.0026
4. Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, et al. Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell. 2017;65(6):1122-35. e5. doi:10.1016/j.molcel.2017.02.008
5. Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, et al. The interaction between er and nfκb in resistance to endocrine therapy. Breast Cancer Res. 2012;14(4):212. doi:10.1186/bcr3196
6. Sun Y, Guan Z, Liang L, Cheng Y, Zhou J, Li J, et al. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int J Oncol. 2016;48(1):225-34. doi:10.3892/ijo.2015.3256
7. Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem. 2012;363(1-2):385-93. doi:10.1007/s11010-011-1191-9
8. Alamolhodaei NS, Behravan J, Mosaffa F, Karimi G. Mir 221/222 as new players in tamoxifen resistance. Curr Pharm Des. 2017;22(46):6946-55. doi:10.2174/1381612822666161102100211
9. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res. 1988;79(3):285-96. doi:10.1111/j.1349-7006.1988.tb01588.x
10. Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723-37. doi:10.1111/1440-1681.12581
11. Kauffmann HM, Keppler D, Gant TW, Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol. 1998;72(12):763-8. doi:10.1007/s002040050571
12. Maciejczyk A, Jagoda E, Wysocka T, Matkowski R, Gyorffy B, Lage H, et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res. 2012;18(2):331-42. doi:10.1007/s12253-011-9449-9
13. Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016;370(1):153-64. doi:10.1016/j.canlet.2015.10.010
14. Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol. 2010;37(1):115-20. doi:10.1111/j.1440-1681.2009.05252.x
15. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573-84. doi:10.1038/nrc2167
16. Martin JD, Panagi M, Wang C, Khan TT, Martin MR, Voutouri C, et al. Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment. ACS Nano. 2019; 25;13(6):6396-408. doi:10.1021/acsnano.8b07865
17. Gately D, Howell S. Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer. 1993;67(6):1171-6. doi:10.1038/bjc.1993.221
18. Comsa E, Nguyen KA, Loghin F, Boumendjel A, Peuchmaur M, Andrieu T, et al. Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition. Future Med Chem. 2018;10(11):1349-60. doi:10.4155/fmc-2017-0308
19. Hill DP, Harper A, Malcolm J, McAndrews MS, Mockus

SM, Patterson SE, et al. Cisplatin-resistant triple-negative breast cancer subtypes: Multiple mechanisms of resistance. BMC Cancer. 2019;19(1):1039. doi:10.1186/s12885-019-6278-9

20. Cui Y, König J, Buchholz U, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55(5):929-37.

21. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996;56(18):4124-9.

22. Myint K, Biswas R, Li Y, Jong N, Jamieson S, Liu J, et al. Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Sci Rep. 2019;9(1):2245. doi:10.1038/s41598-019-38667-8

23. Sandusky G, Mintze K, Pratt S, Dantzig A. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology. 2002;41(1):65-74. doi:10.1046/j.1365-2559.2002.01403.x

24. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Takamura M, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23(4):965-72. doi:10.3892/or_00000721

25. Rose C, Andersen K, Mouridsen H, Thorpe S, Pedersen B, Blichert-Toft M, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985;325(8419):16-9. doi:10.1016/s0140-6736(85)90966-3

26. Jiang Q, Zheng S, Wang G. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future Med Chem. 2013;5(9):1023-35. doi:10.4155/fmc.13.63

27. Cronin-Fenton DP, Damkier P, Lash TL. Metabolism and transport of tamoxifen in relation to its effectiveness: New perspectives on an ongoing controversy. Future Oncol. 2014;10(1):107-22. doi:10.2217/fon.13.168

28. Krisnamurti DG, Louisa M, Anggraeni E, Wanandi SI. Drug efflux transporters are overexpressed in short-term tamoxifen-induced MCF-7 breast cancer cells. Adv Pharmacol Sci. 2016;2016:6702424. doi:10.1155/2016/6702424

29. Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: Tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013;23(11):643-7. doi:10.1097/FPC.0b013e3283656bc1

30. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer. 2007;14(2):293-303. doi:10.1677/ERC-06-0016

31. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPS/ABCCS) in cancer chemotherapy and genetic diseases. FEBS J. 2011;278(18):3226-45. doi:10.1111/j.1742-4658.2011.08235.x

32. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8):1287-93. doi:10.1200/JCO.2009.25.7246

33. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on p-glycoprotein expression and functionality. J Pharm Pharm Sci. 2004;7(3):359-71.

34. Malekshah OM, Lage H, Bahrami AR, Afshari JT, Behravan J. PXR and NF-KB correlate with the inducing effects of IL-1β and TNF-α on ABCG2 expression in breast cancer cell lines. Eur J Pharm Sci. 2012;47(2):474-80. doi:10.1016/j.ejps.2012.06.011

35. Berguetti T, Quintaes LSP, Hancio T, Robaina MC, Cruz AL, C Maia R, et al. TNF-α modulates p-glycoprotein expression and contributes to cellular proliferation via extracellular vesicles. Cells. 2019;8(5):500. doi:10.3390/cells8050500

36. Rinkenbaugh AL, Baldwin AS. The NF-KB pathway and cancer stem cells. Cells. 2016;5(2):16. doi:10.3390/cells5020016

37. Frasor J, El-Shennawy L, Stender JD, Kastrati I. NF-KB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol. 2015;418:235-9. doi:10.1016/j.mce.2014.09.013

38. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF-KB cooperativity at adjacent response elements. J Biol Chem. 2010;285(41):31100-6. doi:10.1074/jbc.M110.155309

39. Jiang X, Chen C, Gu S, Zhang Z. Regulation of abcg2 by nuclear factor kappa b affects the sensitivity of human lung adenocarcinoma a549 cells to arsenic trioxide. Environ Toxicol Pharmacol. 2018;57:141-50. doi:10.1016/j.etap.2017.12.011

40. Chang FW, Fan HC, Liu JM, Fan TP, Jing J, Yang CL, et al. Estrogen enhances the expression of the multidrug transporter gene ABCG2—increasing drug resistance of breast cancer cells through estrogen receptors. Int J Mol Sci . 2017;18(1):163. doi:10.3390/ijms18010163

41. Mosaffa F, Lage H, Afshari JT, Behravan J. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res. 2009;58(10):669-76. doi:10.1007/s00011-009-0034-6

42. Malekshah OM, Bahrami AR, Afshari JT, Mosaffa

F, Behravan J. Correlation between pxr and ABCG2 patterns of mRNA expression in a MCF-7 breast carcinoma cell derivative upon induction by proinflammatory cytokines. DNA Cell Biol. 2011;30(1):25-31. doi:10.1089/dna.2010.1074

43. Ghandadi M, Behravan J, Abnous K, Ehtesham Gharaee M, Mosaffa F. TNF-α exerts cytotoxic effects on multidrug resistant breast cancer MCF-7/MX cells via a non-apoptotic death pathway. Cytokine. 2017;97:167-74. doi:10.1016/j.cyto.2017.06.014

44. Mantovani A. The inflammation–cancer connection. FEBS J. 2018;285(4):638-40. doi:10.1111/febs.14395

45. Zhang Z, Lin G, Yan Y, Li X, Hu Y, Wang J, et al. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells. Oncogene. 2018;37(25):3456-70. doi:10.1038/s41388-018-0221-4

46. Lee G, Piquette-Miller M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci. 2003;92(11):2152-63. doi:10.1002/jps.10493

47. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013;59(1):85-93. doi:10.1373/clinchem.2012.185363

48. Safaei R, Holzer AK, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to pt drugs. J Inorg Biochem. 2004;98(10):1607-13. doi:10.1016/j.jinorgbio.2004.05.006

49. Nakagawa M, Nomura Y, Kohno K, Ono M, Mizoguchi H, Ogata J, et al. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J Urol. 1993;150(6):1970-3. doi:10.1016/s0022-5347(17)35948-7

50. Fujii Ri, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res. 1994;85(4):426-33. doi:10.1111/j.1349-7006.1994.tb02376.x

51. Biswas R, Bugde P, He J, Merien F, Lu J, Liu DX, et al. Transport-mediated oxaliplatin resistance associated with endogenous overexpression of MRP2 in Caco-2 and PANC-1 cells. Cancers. 2019;11(9):1330. doi:10.3390/cancers11091330

52. Hjorth CF, Nielsen AS, Sorensen HT, Lash TL, Damkier P, Hamilton-Dutoit S, et al. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: A danish population-based nested case-control study. Acta Oncol. 2019;58(2):168-74. doi:10.1080/0284186X.2018.1537508

53. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1-24. doi:10.1016/j.pharmthera.2017.12.012

54. Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: A role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat . 2012;133(2):459-71. doi:10.1007/s10549-011-1766-x

55. Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, et al. The interaction between er and nfkappab in resistance to endocrine therapy. Breast Cancer Res. 2012;14(4):212. doi:10.1186/bcr3196

56. DeGraffenried LA, Chandrasekar B, Friedrichs W, Donzis E, Silva J, Hidalgo M, et al. Nf-κb inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 2004;15(6):885-90. doi:10.1093/annonc/mdh232

57. Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, et al. The nuclear transcription factor κb/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005;11(23):8398-402. doi:10.1158/1078-0432.CCR-05-0885

58. Hakim MS, Ding S, Chen S, Yin Y, Su J, van der Woude CJ, et al. TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. Virus Res. 2018; 253:28-37. doi:10.1016/j.virusres.2018.05.022

59. Balasubramaniyan N, Ananthanarayanan M, Suchy FJ. Nuclear factor-kappab regulates the expression of multiple genes encoding liver transport proteins. Am J Physiol Gastrointest Liver Physiol. 2016;310(8):G618-28. doi:10.1152/ajpgi.00363.2015

60. Bauer B, Hartz AM, Miller DS. TNF-α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol pharmacol. 2007;71(3):667-75. doi:10.1124/mol.106.029512